Today: 13 December 2025
Subscribe
Browse Tag

FDA

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

(SEO): Pfizer stock (NYSE: PFE) held firm after the bell on Dec. 12, 2025. Here’s the full roundup of today’s headlines, analyst targets, and what to watch before the next market session. Pfizer, Inc. (NYSE: PFE) wrapped up Friday’s session
13 December 2025
 ·  ·  ·  · 
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer Inc. (NYSE: PFE) ended the Friday, December 12, 2025 session slightly higher—and moved only modestly in after-hours trading—after a busy day of headline-driven catalysts. Investors weighed a newly declared $0.43 quarterly dividend, fresh FDA-related reporting tied to COVID-19 vaccine
13 December 2025
 ·  ·  ·  · 
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up
12 December 2025
 ·  ·  ·  ·  · 
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY)
12 December 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop